The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group.

BACKGROUND Patients with hypertension and renal-artery stenosis are often treated with percutaneous transluminal renal angioplasty. However, the long-term effects of this procedure on blood pressure are not well understood. METHODS We randomly assigned 106 patients with hypertension who had atherosclerotic renal-artery stenosis (defined as a decrease in luminal diameter of 50 percent or more) and a serum creatinine concentration of 2.3 mg per deciliter (200 micromol per liter) or less to undergo percutaneous transluminal renal angioplasty or to receive drug therapy. To be included, patients also had to have a diastolic blood pressure of 95 mm Hg or higher despite treatment with two antihypertensive drugs or an increase of at least 0.2 mg per deciliter (20 micromol per liter) in the serum creatinine concentration during treatment with an angiotensin-converting-enzyme inhibitor. Blood pressure, doses of antihypertensive drugs, and renal function were assessed at 3 and 12 months, and patency of the renal artery was assessed at 12 months. RESULTS At base line, the mean (+/-SD) systolic and diastolic blood pressures were 179+/-25 and 104+/-10 mm Hg, respectively, in the angioplasty group and 180+/-23 and 103+/-8 mm Hg, respectively, in the drug-therapy group. At three months, the blood pressures were similar in the two groups (169+/-28 and 99+/-12 mm Hg, respectively, in the 56 patients in the angioplasty group and 176+/-31 and 101+/-14 mm Hg, respectively, in the 50 patients in the drug-therapy group; P=0.25 for the comparison of systolic pressure and P=0.36 for the comparison of diastolic pressure between the two groups); at the time, patients in the angioplasty group were taking 2.1+/-1.3 defined daily doses of medication and those in the drug-therapy group were taking 3.2+/-1.5 daily doses (P<0.001). In the drug-therapy group, 22 patients underwent balloon angioplasty after three months because of persistent hypertension despite treatment with three or more drugs or because of a deterioration in renal function. According to intention-to-treat analysis, at 12 months, there were no significant differences between the angioplasty and drug-therapy groups in systolic and diastolic blood pressures, daily drug doses, or renal function. CONCLUSIONS In the treatment of patients with hypertension and renal-artery stenosis, angioplasty has little advantage over antihypertensive-drug therapy.

[1]  W. Mali,et al.  Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial , 1999, The Lancet.

[2]  P. Krijnen,et al.  The Dutch Renal Artery Stenosis Intervention Cooperative (DRASTIC) Study: rationale, design and inclusion data. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[3]  J. Webster,et al.  Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis , 1998, Journal of Human Hypertension.

[4]  Pierre-François Plouin,et al.  Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. , 1998, Hypertension.

[5]  Novick Ac.  Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. , 1997 .

[6]  P. Krijnen,et al.  The place of renal scintigraphy in the diagnosis of renal artery stenosis. Fifteen years of clinical experience. , 1997, Archives of internal medicine.

[7]  R. Volkmann,et al.  Treatment of renovascular hypertension: one year results of renal angioplasty. , 1995, Kidney international.

[8]  G. Chatellier,et al.  Restenosis after a first percutaneous transluminal renal angioplasty. , 1993, Hypertension.

[9]  Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. American Society of Hypertension. , 1992, American journal of hypertension.

[10]  J. Nally,et al.  Diagnostic criteria of renovascular hypertension with captopril renography. A consensus statement. , 1991, American journal of hypertension.

[11]  J. Edwards,et al.  Role of duplex scanning for the detection of atherosclerotic renal artery disease. , 1991, Kidney international.

[12]  J. Laragh,et al.  Captopril renography in the diagnosis of renal artery stenosis: accuracy and limitations. , 1991, The American journal of medicine.

[13]  T. Craven,et al.  Renal duplex sonography: evaluation of clinical utility. , 1990, Journal of vascular surgery.

[14]  P. Waller,et al.  Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. , 1990, BMJ.

[15]  A. Donker,et al.  Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty. , 1986, Nephron.

[16]  B. Meier,et al.  TREATMENT OF RENOVASCULAR HYPERTENSION WITH PERCUTANEOUS TRANSLUMINAL DILATATION OF A RENAL-ARTERY STENOSIS , 1978, The Lancet.

[17]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[18]  M. Maxwell,et al.  Renovascular occlusive disease. Results of operative treatment. , 1975, JAMA.

[19]  J. Foster,et al.  Renovascular hypertension. , 1975, Journal of the Tennessee Medical Association.

[20]  M Zelen,et al.  The randomization and stratification of patients to clinical trials. , 1974, Journal of chronic diseases.

[21]  P. E. Bernatz,et al.  Renal and renovascular hypertension. A reasoned approach to diagnosis and management. , 1974, Archives of internal medicine.

[22]  H. Goldblatt,et al.  STUDIES ON EXPERIMENTAL HYPERTENSION I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA , 1934 .